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ABSTRACT
Antimicrobial resistance genes in pathogenic bacteria belong to the most rapidly evolving DNA
sequences, which results in an enormous structural diversity of resistance effectors. Structural
modiﬁcations of resistance genes by mutation and recombination, together with a multitude of events
that stimulate their mobility and expression, allow microorganisms to survive in environments
saturated with antimicrobial agents of various types and generations. Genes coding for b-lactamases
in Gram-negative bacteria are a fascinating example of this multifocal and multidirectional evolution,
with the extended-spectrum b-lactamases (ESBLs) being one of the most spectacular ‘achievements’.
Some of the ESBLs known today are ‘ready-to-use’ enzymes in their natural producers but these are
often of low pathogenic potential, or none at all. The problem appears upon mobilisation of a gene
encoding such an ESBL, and its acquisition and sufﬁcient expression by a more virulent organism.
Many ESBLs are generated by mutations in genes coding for broad-spectrum enzymes, which have
been mobile since at least the 1960s and which have disseminated very widely in populations of
pathogenic bacteria. Strong selection pressure exerted by antimicrobial use, especially with newer-
generation b-lactam antibiotics, efﬁciently promotes these two modes of ESBL emergence and
subsequent spread. It also stimulates further evolution of ESBLs by accumulation of other mutations
with an astonishing variety of effects on b-lactamase structure and activity. Remarkably, more than
300 natural ESBL variants have been identiﬁed since the mid-1980s but in-vitro studies suggest that
ESBL evolution has certainly not come to an end; they may also help in predicting future
developments. The aim of this review is to brieﬂy overview the role of various mutations in ESBL
evolution.
Keywords b-lactamase, ESBL, evolution, mutation, review
Clin Microbiol Infect 2008; 14 (Suppl. 1): 11–32
INTRODUCTION
Evolution at the molecular level involves the
gradual accumulation of mutations (and other
changes) in DNA sequences under the selective
constraints of the environment [1]. Once a muta-
tion affects the structure of a gene product, or
gene expression, it may cause loss of function,
cause gain of function, or be neutral. The spec-
trum of possible mutational effects may be wide,
and a loss-of-function mutation may lead to the
full or partial reduction of a gene product activity,
whereas a gain-of-function mutation may confer
either a new activity or enhance an existing one.
Moreover, a single mutation may cause both a
loss and gain of function, due to a structure-based
‘trade-off’ between the two functions, or between
stability and activity of the gene product [2].
The rate of evolution of DNA sequences is
highly variable [1]. Among the DNA sequences
that evolve most rapidly are the bacterial genes
responsible for antimicrobial resistance. Resis-
tance often evolves rapidly after a new antibiotic
enters into clinical practice, with this rapidity
reﬂecting several characteristics of microorgan-
isms, such as their large population sizes, short
generation times, and the expansion of resistance
by transmission of mobile genes. Other key
factors include the strong selective pressure of
antimicrobial use in humans, animals, and agri-
culture [3], the presence of mutational hot-spots
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in resistance genes, and the high structural ﬂex-
ibility of many resistance effectors [4].
b-Lactamases, especially those of Gram-nega-
tive bacteria, provide an excellent example of the
evolution of resistance mechanisms. Their history
has been extensively analysed on various time
scales. Long-term analyses, based on protein
sequences, have resulted in views of genealogy
of the fundamental lineages of b-lactamase clas-
ses A, B, C and D [5] and their evolutionary
relationship to penicillin-binding proteins [6], or
of b-lactamase families [7]. Shorter-term studies
aim to reveal the evolution of variants, often via
single sequence changes (microevolution) [8],
sometimes in speciﬁc geographical regions
[9,10]. These analyses are carried out on naturally
occurring b-lactamase variants by protein or DNA
sequence comparisons. In the former case, the
studies reveal only the evolutionary trends within
b-lactamase families; in the latter case, the studies
precisely reconstruct the history of particular
enzyme lineages, considering also silent muta-
tions and genetic context. Studies on laboratory
mutants, obtained by in-vitro mutagenesis or via
directed evolution, contribute to our understand-
ing of the evolutionary past, and allow future
predictions [11].
The largest structural ⁄ evolutionary group of
b-lactamases is Ambler class A [12], which in-
cludes the vast majority of the Bush, Jacoby and
Medeiros group 2 with ‘penicillinases, cephalo-
sporinases and broad-spectrum b-lactamases that
are generally inhibited by active site-directed b-
lactamase inhibitors’ [5]. Intensive evolution of
class A b-lactamases has resulted in great struc-
tural diversity, with numerous families and
subfamilies, as well as recent modiﬁcations
distinguishing multiple variants. Minor structural
diversity can confer major differences in biochem-
ical properties, affecting substrate spectra, inhibi-
tion proﬁles and, consequently, the phenotypes of
resistant pathogens. Class A includes species-
speciﬁc and ⁄ or acquired b-lactamases that are
expressed constitutively or inducibly [13].
TEM AND SHV b -LACTAMASES:
CONVERTING A BROAD-SPECTRUM
ENZYME INTO AN EXTENDED-
SPECTRUM b -LACTAMASE (ESBL)
TEM and SHV b-lactamases are the most studied
class A enzymes. Both families have had a rela-
tively long period of evolution in the ‘clinical’ era,
resulting in the observation of high numbers of
structural modiﬁcations, many of them affecting
biochemical properties [14,15]. Moreover, owing
to the very high prevalence of TEM and SHV
b-lactamases in Gram-negative bacteria (mostly
the Enterobacteriaceae), the enzymes have had a
strong impact on the clinical context and the
epidemiology of bacterial infections all over the
world. The TEM and SHV families, as we now
observe them, may be traced back to a few
parental enzymes, namely TEM-1, TEM-2, SHV-
1 and SHV-11. The deeper origins of TEM
b-lactamases remain unrevealed, with all TEM
variants being identiﬁed as acquired enzymes,
encoded by mobile genes [13,15]. On the other
hand, the parental SHV b-lactamases are speciﬁc
for Klebsiella pneumoniae, and the mobile blaSHV
genes are the descendants of several escapes from
the chromosome of this species [16]. The micro-
evolution of TEM and SHV b-lactamases has been
extremely intensive in recent years, as demon-
strated by the almost exponential growth in
numbers of variants identiﬁed since the mid-
1980s. The number of recognised polymorphic
sites in amino-acid sequences has rapidly in-
creased as well, especially in the case of SHV
enzymes, with c. 160 TEM and 100 SHV amino-
acid sequences submitted to the http://www.
lahey.org/studies/webt.asp website. These differ
from each other in c. 50 positions. This number
seems likely to increase, since, in a saturation
mutagenesis study, 220 out of 263 amino-acid
positions of the mature TEM-1 protein tolerate
mutations, with the enzyme retaining good
hydrolytic activity against ampicillin [17]. Among
both the TEM and SHV families, three major types
of activity have been identiﬁed: those of the
broad-spectrum b-lactamases, the ESBLs, and the
inhibitor-resistant b-lactamases.
ESBLs are the most ‘spectacular’ result of this
microevolution [5,13,15,18–21]. These enzymes
have an expanded substrate spectrum towards
oxyimino-b-lactams (oxyiminocephalosporins
and aztreonam). The responsible mutations,
therefore, result in gain of function, but because
the parent broad-spectrum enzymes still have
trace activity against oxyimino-compounds, the
ESBL activity should be seen as an improved
activity rather than as something entirely new.
This gain is almost always accompanied by
partial loss of activity against penicillins [22].
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The ﬁrst natural ESBLs were identiﬁed in the
mid-1980s [23,24] but soon they became widely
disseminated in Gram-negative populations
worldwide. The major factor responsible for this
accumulation is the strong selective pressure of
oxyimino-b-lactam use. TEM and SHV ESBLs
have been extensively studied in terms of bio-
chemistry, structural biology, molecular biology
and clinical microbiology [13,15,18–21].
Among the many substitutions observed in
TEM and SHV ESBLs, several are more or less
directly associated with ESBL activity. These
include mutations at positions Glu104 (TEM),
Ala146 (SHV), Gly156 (SHV), Arg164 (TEM),
Leu169 (SHV), Asp179 (SHV and TEM), Arg205
(SHV), Ala237 (TEM), Gly238 (TEM and SHV),
and Glu240 (TEM and SHV) [14,22,25–27]. Most of
these positions are in, or very close to, the
oxyanion pocket that contains the enzyme’s active
site, and which itself is located at the interface
between the two major domains of a class A
b-lactamase molecule (Fig. 1). Speciﬁcally, most
substitutions affect amino-acid residues within
the B3 b-strand or W-loop [11,14,22]. Substitutions
at positions 238, 164 and 179 seem to be especially
critical for ESBL activity, and occur in the vast
majority of TEM- and SHV-type ESBLs (http://
www.lahey.org/studies/webt.asp). Single mut-
ants, e.g., TEM-12, TEM-19, SHV-2, SHV-8 and
SHV-24, have been identiﬁed in clinical isolates
with an ESBL phenotype [24,28–32] but, except for
SHV-2 [9,33–37], such enzymes are relatively rare.
Glycine at position 238 (B3 b-strand) is usually
replaced by serine in ESBLs (32 TEMs and 22
SHVs) (http://www.lahey.org/studies/webt.
asp), but alanine was observed in three natural
SHV variants (SHV-13, -18 and -29) [38–40]. The
characteristics of the sole TEM enzyme with
Asp238, TEM-111 (GenBank AF468003), have not
yet been published. The replacement of arginine
at position 164 (W-loop) has so far been observed
only in TEMs, either by serine, histidine or
cysteine (with 23, 16 and three variants, respec-
tively). Until recently, mutations of Asp 179 (W-
loop) had been identiﬁed only in natural SHV
variants, with replacements by glycine, alanine or
asparagine (one variant each) (http://www.
lahey.org/studies/webt.asp). Now TEM-126 has
been found with a corresponding aspartate-
to-glutamate substitution [41], while Asp179Gly ⁄ -
Tyr mutants of TEM were selected only in
directed evolution studies [42]. From the numbers
of variants with mutations at positions 238, 164
and 179, and the sequence diversity of their
corresponding genes, it is clear that each of the
mutations must have been selected on multiple
independent occasions.
Much effort has been applied to understand-
ing the effect of common ESBL-type mutations
on b-lactamase structure, biochemical properties,
and the phenotypes of a producer organism.
In these analyses, carried out on a variety of
artiﬁcial single mutants, both the nature (e.g.,
hydrogen-bonding potential) and the side chain
volume of the new residue are considered. In the
case of the Gly238 mutations, various models are
proposed, including improvement of substrate
afﬁnity by formation of extra hydrogen bonds to
oxyimino-b-lactams (Gly238Ser in TEM) or by
conformational changes leading to the expansion
of the active site cavity, by displacement of the
B3 b-strand or W-loop due to formation of novel
intramolecular hydrogen bonds and ⁄ or steric
conﬂicts caused by a larger-volume side chain
(Gly238Ser and Gly238Ala) [14,22,43]. Recent
crystallographic studies on TEM-52 [11], TEM-
64 [44] and SHV-2 (which has only a single
substitution) [45] conﬁrm the concept of the
signiﬁcant B3 b-strand displacement, with new
intramolecular hydrogen bonds in the case of the
Gly238Ser mutation. This conformation change
greatly enlarges the oxyanion cavity. Residues
Arg164 and Asp179 strongly interact with each
other, forming an ionic bond across the ‘neck’ of
Fig. 1. Tertiary structure of a class A b-lactamase with
positions important for activity indicated. Reproduced
with permission from Matagne et al., Biochem J 1998; 330:
581–598.  the Biochemical Society.
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the W-loop, which is critical for conformation and
stability. Mutations Arg164Ser ⁄His ⁄Cys and
Asp179Gly ⁄Ala ⁄Asn disrupt this salt bridge,
probably causing complete reorganisation of
hydrogen bonds in the region, along with a
signiﬁcant conformational change at the entrance
to the active site [14,41]. It is interesting that
Arg164 mutations have been observed only in
TEM enzymes so far, whereas those at Asp179
were, for a long time, found only in SHV
enzymes. For the TEM-126 enzyme with
Asp179Glu and Met182Thr mutations, subtle
conformational changes due to modiﬁed hydro-
gen bonds at the W-loop’s neck have been
postulated [41].
Table 1 shows catalytic efﬁciencies, kcat ⁄Km, or
relative rates of hydrolysis, Vrel, against selected
substrates as evaluated for a set of single mutants
at positions 238, 164 and 179, and for the parent
enzymes TEM-1 and SHV-1. Several artiﬁcial
mutants corresponded to the natural b-lactamas-
es TEM-19 (Gly238Ser), TEM-12 (Arg164Ser) and
SHV-2 (Gly238Ser), whereas SHV-24 (Asp179Gly)
itself was a natural variant [32,43,46,47]. The
single TEM Gly238Ala mutant has not been
identiﬁed in nature so far. All these variants
had signiﬁcantly increased activity against
oxyimino-b-lactams. With the TEM-12 Arg164Ser
mutant, the increase mostly affected ceftazidime
(130-fold increase of kcat ⁄Km) [46], whereas the
TEM-19 Gly238Ser mutant demonstrated compa-
rable increases in activity against both ceftazi-
dime and cefotaxime (51-fold and 52-fold
increase of kcat ⁄Km, respectively) [43]. In general,
these increases are rather small, and, in the case
of the TEM-12 enzyme, for example, the rates of
ceftazidime and cefotaxime hydrolysis are below
10% that of benzylpenicillin, which is considered
as a breakpoint for identiﬁcation of an enzyme as
an ESBL [5]. At the same time, signiﬁcant
reductions of hydrolytic activity toward penicil-
lins occurred, especially profound in the case of
TEM-12 (93-fold decrease of kcat ⁄Km against
ampicillin) [46] and TEM-19 (benzylpenicillin,
50-fold; ampicillin, 25.5-fold) [43]. A variety of
effects were observed with narrow-spectrum
cephalosporins, depending on the enzyme, muta-
tion type, and the substrate. MICs of representa-
tive b-lactams against Escherichia coli recombinant
strains producing various single ESBL mutants
are presented in Table 2. In accordance with the
enzyme activity changes, MICs of oxyimino-b- T
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lactams were increased when compared with
TEM-1 or SHV-1 producers, but usually only to
relatively low levels [43,47–49]. Signiﬁcant
quantitative differences could be seen between
particular experimental models, reﬂecting differ-
ences among the various plasmid vectors and
E. coli host strains used. For producers of
enzymes with Arg164 and Asp179 mutations,
MICs of ceftazidime were much higher than
those of cefotaxime [48,49]. The MICs of penicil-
lins were lower than those for TEM-1 and SHV-1
producers, although high-level resistance was
usually retained.
The decrease in activity against penicillins
accompanying major ESBL-type mutations is a
good example of the trade-off between different
protein functions. The conformational changes
that result from these mutations lead to struc-
tural defects that affect protein folding or stabil-
ity [50,51]. The TEM Gly238Ser mutant (TEM-19)
had lower thermal stability, was more prone to
trypsin proteolysis and equilibrium denaturation
by guanidinium hydrochloride [52] and showed
increased aggregation as compared with TEM-1
[53]. The ESBL-type mutations observed in
nature are not the only ones to confer ESBL
activity. Other substitutions do so in in-vitro
studies, but some of these are associated with a
much greater misbalance between the two activ-
ities and a greater decrease in activity against
penicillins [42, 54, 55]. A good example is the
TEM mutant Asp179Gly, which has never been
found in nature. The amoxycillin MIC for the
producer was only 64 mg ⁄L, limiting the chance
of selection in clinical environments, where
penicillins are still in use [42]. The only natural
TEM Asp179 mutant, TEM-126, has glutamic
acid, which resembles the original aspartic acid,
at this position; moreover, TEM-126 also carries
the stabilising mutation Met182Thr, discussed in
detail below [41]. A similar situation arises with
substitution of arginine for leucine at posi-
tion 169. A TEM Leu169Arg mutant was ob-
tained in an in-vitro evolution study, and its
producer had a signiﬁcant increase in ceftazi-
dime MIC when compared to the parent TEM-1
producer (4 vs. 0.25 mg ⁄L) and a major decrease
in amoxycillin MIC (8 vs. >1024 mg ⁄L) [42]. A
natural SHV ESBL variant carrying the single
Leu169Arg mutation was identiﬁed and desig-
nated SHV-57. The enzyme showed a 100 000-
fold decrease of kcat ⁄Km against benzylpenicillin,T
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but the ampicillin MIC for the producer was
>32 mg ⁄L. It is proposed that mutation at
position 169 induces a signiﬁcant conformational
change of Asn170, one of the critical residues in
the W-loop [26]. The negative effects of the ESBL
mutations may concern not only structure and
stability but also expression. Hujer et al. [47]
have found that SHV Gly238 mutants are
expressed at lower levels than SHV-1, owing to
decreased translation. This phenomenon has not
been observed for TEM ESBLs with single
mutations—another signiﬁcant difference be-
tween TEMs and SHVs.
As already mentioned, the levels of resistance
to oxyimino-b-lactams are low in E. coli recom-
binant strains with single ESBL mutants, and
this is also true for many clinical isolates that
appear to be susceptible at CLSI breakpoints.
There are several ways for bacteria to ‘improve’
their resistance. One way is by acquiring
another resistance mechanism, often by lower-
ing permeability of the outer-membrane [31,56–
58]. Bla´zquez et al. analysed the inﬂuence of
outer-membrane permeability on the resistance
level conferred by single-mutant ESBLs by
comparing the MICs for E. coli strains with or
without porin OmpF, and producing either
TEM-12 or TEM-19, expressed from the same
plasmid vector. The results, shown in Table 3,
demonstrated the very signiﬁcant effect of porin
alteration on the resistance to oxyimino-b-lac-
tams [48]. Another way of increasing resistance
is by raising the ESBL expression by promoter
mutations or replacements (e.g., those delivered
by insertion sequences, IS) or by ESBL gene
copy ampliﬁcation [59–63]. Randegger et al.
investigated the effect of weak vs. strong pro-
moters, located in front of various blaSHV genes,
on resistance levels of isogenic producer E. coli
strains. A strong promoter was better able to
increase resistance to oxyimino-b-lactams in
strains expressing the single mutants SHV-2
Gly238Ser and SHV-8 Asp179Asn (Table 3) [49].
Various combinations of multiple factors must
be responsible for the wide ranges of b-lactam
MICs observed in clinical isolates producing
single-mutant ESBLs [28,31,32]. In a study by
Jutersˇek et al. [37], MICs of cefotaxime for a
group of SHV-2-producing K. pneumoniae iso-
lates from a single hospital in Slovenia ranged
from 1 to 32 mg ⁄L, and those of ceftazidime
from 0.5 to 16 mg ⁄L. Ta
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MULTIPLE MUTATIONS IN TEM AND
SHV ESBLS
The third way of increasing ESBL-related resis-
tance is the further evolution of the b-lactamases
themselves, often by further mutations at Glu240
and Glu104. Glu240 is very often replaced in
natural TEM (n = 27) and SHV (n = 17) enzymes,
and is almost always changed to a basic amino
acid, lysine (http://www.lahey.org/studies/
webt.asp) or, rarely, arginine (TEM-137 [64] and
SHV-86 (GenBank DQ328802)). TEM-149 (Gen-
Bank DQ105529) is the only enzyme with valine
in this position. Except for SHV-31 [65] and SHV-
97 (GenBank EF373973), the Glu240Lys ⁄Arg
mutation has always been identiﬁed in enzymes
carrying one of the major ESBL-type mutations at
position 238 or 164 (http://www.lahey.org/stud-
ies/webt.asp). The role of the mutation, however,
has been well-studied with in-vitro mutants,
including single TEM Glu240Lys mutants
[66,67]. Position 240 is located at the end of the
B3 b-strand, and the replacement of glutamic acid
by a basic residue results in the formation of an
electrostatic bond with the carboxyl group of the
oxyimino substituent in ceftazidime and aztreo-
nam. Most probably, the mutation does not have
much effect on the enzyme structure [14]. Since
several pairs of natural ESBLs show a difference
only in the presence of Glu240Lys, e.g., TEM-12
and TEM-10 [68], TEM-25 and TEM-48 [69], and
SHV-2 and SHV-5 [70], it follows that the muta-
tion probably appeared independently several
times in the evolution of TEM and SHV ESBLs.
Mutation at position 104 has been found only
in the TEM family so far, occurring in as many as
41 variants and coexisting with mutations of
Gly238 or Arg164 in 36 of these. In all cases, the
glutamic acid residue is replaced by the basic
residue lysine (http://www.lahey.org/studies/
webt.asp). The single Glu104Lys mutant of
TEM-1 identiﬁed in nature is TEM-17 [71] and
that of TEM-2 is TEM-18 [72], whereas the
consequences were studied in detail for a labora-
tory mutant [66]. Owing to protein folding,
position 104 is located close to the entrance to
the active site, and thus, as for position 240,
Lys104 most probably interacts with carboxyl
groups of ceftazidime and aztreonam [14]. It is
also postulated that Glu104Lys stabilises the
cavity structure affected by the mutation Gly238-
Ser [22], and this was conﬁrmed by crystallo-
graphic study of the TEM-52 enzyme [11]. In
several pairs, the TEM enzymes differ only by the
presence of the mutation Glu104Lys, e.g., TEM-1
vs. TEM-17 [71], TEM-2 vs. TEM-18 [72], or TEM-
25 vs. TEM-4 [10,29], suggesting several indepen-
dent selections in nature.
In the study by Sowek et al. [66], mutations
Glu240Lys and Glu104Lys behaved similarly to
each other (Table 4). Both single artiﬁcial mutants,
TEM Glu240Lys and TEM-17 Glu104Lys, were
more active against ceftazidime than TEM-1 (30-
fold and 22.5-fold increase in kcat ⁄Km, respec-
tively), although the difference was much less
profound than for TEM-12 Arg164Ser (650-fold).
On the other hand, Venkatachalam et al. [67]
studied Glu240Lys in the context of the Gly238Ser
mutation, and observed an increase of kcat ⁄Km for
the single Glu240Lys mutant against ceftazidime
as compared with TEM-1 (85-fold). This change
was comparable to that of TEM-19 Gly238Ser (80-
fold increase in kcat ⁄Km); however, the Glu240Lys
mutant was much less active against cefotaxime
than TEM-19 (2.2-fold and 45.5-fold increases in
kcat ⁄Km, respectively). Both studies demonstrated
a dramatic increase in catalytic efﬁciency against
ceftazidime in the three double mutants, i.e.,
Arg164Ser ⁄Glu240Lys, Glu104Lys ⁄Arg164Ser
and Gly238Ser ⁄Glu240Lys, measured as the
4450-fold, 19 000-fold and 2855-fold increase in
kcat ⁄Km, respectively, as compared with TEM-1.
These double mutants, corresponding to TEM-10,
TEM-26 and TEM-71 [73–75], respectively, were
much more active against ceftazidime (and azt-
reonam) than the single-mutant ESBLs. Mutations
Glu240Lys and Glu104Lys do not signiﬁcantly
affect hydrolysis of penicillins or narrow-spec-
trum cephalosporins [66,67].
The role of Glu240Lys and Glu104Lys muta-
tions is illustrated in Table 5, which shows MIC
data from several studies on E. coli recombinants
and clinical isolates producing various b-lacta-
mases with mutations at positions 240, 104, 238
and 164. The MICs of oxyimino-b-lactams with
single or double mutations at Glu240Lys and
Gly238Ser produced by E. coli recombinants
strictly followed the differences in catalytic efﬁ-
ciency [67]. Similar observations were made in
isogenic E. coli strains producing TEM-2, TEM-18
or TEM-3 (the Glu104Lys ⁄Gly238Ser variant of
TEM-2), with slightly raised MICs of ceftazidime
and cefotaxime for the TEM-18 producer and
dramatically increased MICs of both compounds
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for the TEM-3 producer [72]. Clinical isolates
producing various double-mutant ESBLs at posi-
tions 240 or 104 and 238 or 164 are usually
characterised by clear resistance to oxyimino-b-
lactams, especially in combinations with muta-
tions at position 164 for ceftazidime (Table 6)
[37,73,75–78]. Some such enzymes, e.g., TEM-3,
TEM-10, TEM-26, SHV-5 and SHV-12 (the Gly238-
Ser ⁄Glu240Lys mutants of SHV-1 and SHV-11,
respectively), are among the most widespread
ESBL variants [36,74,76,79–82]. Interestingly, a
remarkable effect on resistance of the Glu104Lys
mutation alone was observed in a study in which
a TEM-17-producing isolate of Capnocytophaga
ochracea was compared with its ESBL-negative
derivative, obtained by plasmid curing. The MICs
of both cefotaxime and ceftazidime were much
reduced by plasmid loss (Table 5) [71]. Similarly,
production of SHV-31, which is a Glu240Lys
mutant of SHV-11, increased the MICs of oxyimi-
no-b-lactams, especially ceftazidime and aztreo-
nam, signiﬁcantly for an E. coli recombinant [65].
There are fewer data concerning the ESBL
mutations Gly156Asp and Arg205Leu. The ﬁrst
of these has been identiﬁed alone in SHV-27 [25],
and together with other mutations in SHV-32 [83],
SHV-45 (GenBank AF547625) and SHV-93 (Gen-
Bank EF373969). The SHV-27-producing K. pneu-
moniae isolate was clearly resistant to cefotaxime
(MIC 96 mg ⁄L) and ceftazidime (MIC 8 mg ⁄L)
[25]. Arg205Leu was found alone in SHV-44
[84], and occurs also in SHV-3 and SHV-4, both
of which also possess major ESBL-type substitu-
tions [85,86]. The MICs of oxyimino-b-lactams for
E. coli recombinant with SHV-44 were not
increased signiﬁcantly [84], although it has been
proposed that the mutation may cause a confor-
mational change that allows such substrates better
access to the active site [14].
Apart from the mutations that increase oxyi-
mino-b-lactam-hydrolysing activity directly, other
signiﬁcant mutations occur in ESBLs. One such
mutation occurs at position 237 and has so far
been observed exclusively in the TEM family,
occurring in nine variants. In all but one of these,
Ala237 is replaced by threonine; the exception is
TEM-22, with glycine at this position [87]. These
Ala237 mutations have been observed only in
ESBLs, and almost always in those with the
Arg164Ser ESBL-type mutation (http://www.
lahey.org/studies/webt.asp). Ala237Thr was
probably selected in several independent events,
as variants in several pairs differ from each other
only by this substitution, e.g., TEM-10 and TEM-5
[88], TEM-46 and TEM-24 [89], or TEM-85 and
TEM-86 [10]. Position 237 is located in the B3
b-strand, and the Ala237Thr replacement has
been postulated to lead to new hydrogen bond
formation with some substrates (e.g., cefotaxime)
[14].
In the study by Healey et al. [90], the single
laboratory mutant Ala237Thr showed four-fold
higher activity vs. cephalosporin C and cephalo-
thin and ten-fold lower activity against penicillins
than TEM-1. In a comparative analysis of TEM-46
(Gln39Lys ⁄Glu104Lys ⁄Arg164Ser ⁄Glu240Lys)
Table 6. Susceptibility of clinical isolates or Escherichia coli transconjugants producing selected natural double-mutant
TEM and SHV extended-spectrum b-lactamases with mutations Glu240Lys or Glu104Lys
b-Lactam
MIC (mg ⁄L)
TEM-10
(Arg164Ser ⁄
Glu240Lys)
[73]a
TEM-28
(Arg164His ⁄
Glu240Lys)
[78]b
TEM-26
(Glu104Lys ⁄
Arg164Ser)
[76]c
TEM-6
(Glu104Lys ⁄
Arg164His)
[77]d
TEM-71
(Gly238Ser ⁄
Glu240Lys)
[75]e
SHV-5
(Gly238Ser ⁄
Glu240Lys)
[37]f
AMP ⁄AMX >256 NA – 2000 >64 >512
CTX 0.5 8 1 1 8 16
CAZ 64 >32 256 128 32 256
AMP, ampicillin; AMX, amoxycillin; CTX, cefotaxime; CAZ, ceftazidime; NA, not analysed.
aThis study was carried out with Klebsiella pneumoniae clinical isolates producing TEM-10 (Arg164Ser ⁄Glu240Lys).
bThis study was carried out with an E. coli clinical isolate producing TEM-28 (Arg164His ⁄Glu240Lys).
cThis study was carried out with the E. coli J53-2 transconjugant producing TEM-26 (YOU-1) (Glu104Lys ⁄Arg164Ser).
dThis study was carried out with the E. coli C600 transconjugant producing TEM-6 (Glu104Lys ⁄Arg164His).
eThis study was carried out with a K. pneumoniae clinical isolate producing TEM-71 (Gly238Ser ⁄Glu240Lys).
fThis study was carried out with K. pneumoniae clinical isolates producing SHV-5 (Gly238Ser ⁄Glu240Lys).
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and TEM-24 (Gln39Lys ⁄Glu104Lys ⁄Arg164Ser ⁄
Ala237Thr ⁄Glu240Lys), the Ala237Thr mutation
increased catalytic efﬁciency against cephalothin
and cefotaxime, and decreased that against pen-
icillins [89]. These results led to the conclusion
that the mutation stimulates hydrolysis of cep-
hems and decreases that of penams. However,
comparison of TEM-10 (Arg164Ser ⁄Glu240Lys)
and TEM-5 (Arg164Ser ⁄Ala237Thr ⁄Glu240Lys)
[88], and TEM-85 (Leu21Phe ⁄Arg164Ser ⁄Glu240-
Lys ⁄Thr265Met) and TEM-86 (Leu21Phe ⁄ -
Arg164Ser ⁄Ala237Thr ⁄Glu240Lys ⁄Thr265Met)
[10], revealed a more complex picture. A clear
increase in cephalothin and cefotaxime MICs was
accompanied by a decrease in the MICs of
amoxycillin, piperacillin, ceftazidime and aztreo-
nam; therefore, the mutation was described as
modulating activity against particular substrates
(Table 7). It may confer a selective advantage in
clinical environments where a variety of b-lac-
tams are in use [88].
As with position 237, mutation at position 182
has been identiﬁed only in natural TEMmutants so
far. Found in 20 variants, it always entails replace-
ment of methionine by threonine (http://www.
lahey.org/studies/webt.asp). Except in TEM-135
(http://www.lahey.org/studies/webt.asp), the
Met182Thr mutation has always been observed in
ESBLs (18 variants) or inhibitor-resistant b-lacta-
mases (one variant). Some of the enzymeswith this
substitution are characterised by the unusual
combinations of ESBL-type mutations, as with
TEM-106 (Glu104Lys ⁄Met182Thr) (GenBank
AY101578), TEM-124 (Gln6Lys ⁄Glu104Lys ⁄ -
Met182Thr) (GenBank AY327540), and TEM-126
(Asp179Glu ⁄Met182Thr) [41]. The Met182Thr
mutation was probably selected repeatedly on
several independent occasions, in the evolution
of, e.g., TEM-43 from TEM-6 [91], TEM-52 from
TEM-15 [92], or TEM-94 from TEM-4 [10]. Interest-
ingly, position 182 is relatively far away from the
active site; however, it is located in the important
hinge region between the two major class A
b-lactamase domains. Crystallographic study of
TEM-52 showed that Thr182 formed new intramo-
lecular hydrogen bondswith two residues of one of
the domains,Glu63 andGlu64,whichmay stabilise
the active site topology reorganised by other
mutations [11].
Huang and Palzkill showed that mutation
Met182Thr increased the activity of laboratory
TEM variants with severe structure and ⁄ or sta-
bility defects caused by other mutations. This was
especially profound in the case of mutations at
Leu76 (never observed in nature), which caused
E. coli producers to have 12- to 30-fold lower
ampicillin MICs than the TEM-1 producer. Strains
producing the double-mutant enzymes, TEM
with Leu76Asn ⁄ Ser and Met182Thr, by contrast,
were characterised by ampicillin MICs only 1.5- to
two-fold lower than those for the TEM-1 producer
(Table 7). In another laboratory-selected inhibitor-
Table 7. Susceptibility of Escherichia coli recombinants producing selected artiﬁcial mutant TEM b-lactamases with
mutations Ala237Thr or Met182Thr
b-Lactam
MIC (mg ⁄L)
TEM-1
[88]a
TEM
Ala237Thr
[88]a
TEM
Arg164Ser ⁄
Glu240Lys
(TEM-10)
[88]a
TEM
Arg164Ser ⁄
Ala237Thr ⁄
Glu240Lys
(TEM-5)
[88]a
TEM-1
[50]b
TEM
Met182Thr
(TEM-135)
[50]b
TEM
Leu76Asn
[50]b
TEM
Leu76Asn ⁄
Met182Thr
[50]b
AMP >2048 2048 >2048 1024 3000 2000 100 2000
LOT 32 32 16 128 NA – – –
CTX 0.03 0.03 0.5 4 – – – –
CAZ 0.12 0.12 128 16 – – – –
AMP, ampicillin, LOT, cephalothin; CTX, cefotaxime; CAZ, ceftazidime; NA, not analysed.
aThis study was carried out with E. coli RYC1000 transformants producing TEM-1 or its laboratory mutants; TEM
Arg164Ser ⁄Glu240Lys corresponds to TEM-10, and TEM Arg164Ser ⁄Ala237Thr ⁄Glu240Lys to TEM-5; the TEM Ala237Thr
mutant has not been observed in nature.
bThis study was carried out with E. coli XL1-Blue transformants producing TEM-1 or its artiﬁcial mutants; only the
Met182Thr single mutant has been identiﬁed in nature, TEM-135 (http://www.lahey.org/studies/webt.asp), but no data
on it have been published as yet.
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resistant enzyme with mutations Met69Ile and
Met182Thr (equivalent to natural TEM-32), muta-
tion Met182Thr improved thermal stability com-
pared with the single mutation Met69Ile. These
authors concluded that the mutation acts as a
global suppressor of the defects in b-lactamase
structure or stability caused by the ESBL or
inhibitor resistance (IR) mutations that alter the
active site region [50]. In another study under-
taken by the same group, Met182Thr was shown
to reduce aggregation of the TEM Gly238Ser
mutant enzyme [53]. Similarly, an enzyme-stabil-
ising role was proposed for mutations Ala42Val,
observed naturally in TEM-42 [11,93], and Leu51-
Pro, identiﬁed in TEM-60 [94].
While some mutations confer ESBL activity,
others diminish susceptibility to site-directed
inhibitors (IR-type mutations). These occur at
positions 69, 130, 187, 244, 275 and 276 of TEM
and SHV enzymes, and have been extensively
studied and reviewed [14,95,96]. Since IR muta-
tions do not directly affect b-lactam hydrolysis,
they will not be discussed in detail here. How-
ever, these mutations usually reduce the activity
of TEM-1 against penicillins and, especially,
narrow-spectrum cephalosporins [50,97,98], and
may affect signiﬁcantly any ESBL activity. From
the mid-1990s, scientists have asked: ‘what will
happen when ESBL and IR mutations occur
together in a single enzyme?’ This intriguing
question has been addressed by several laborato-
ries working on artiﬁcial or natural variants
dubbed ‘complex mutant enzymes’. At least nine
natural TEM or SHV b-lactamases with both
ESBL- and IR-type mutations have been identi-
ﬁed, comprising TEM-50, TEM-68, TEM-89, TEM-
109, TEM-121, TEM-125, TEM-151, TEM-152 and
SHV-10 [99–106]. As compared with their ESBL
and IR b-lactamase counterparts (with only one
mutation type) or with classic ESBLs, a compro-
mise in one or both properties was usually
observed (Table 8). TEM-89 and SHV-10 have no
signiﬁcant ESBL activity but are clearly inhibitor-
resistant [101,105], and TEM-125 is a relatively
weak ESBL, but has greatly increased resistance to
inhibitors [104]. TEM-68, TEM-109 and TEM-121
are efﬁcient ESBLs, at least for some oxyimino-
b-lactams, but have only modestly reduced sus-
ceptibility to inhibitors [100,102,103]. Finally,
TEM-50 combines both properties at moderate
levels [99]. Similar observations were made in
studies on laboratory mutants [107–109].
AN SHV ‘CARBAPENEMASE’
Mutation at position 146 deserves a separate dis-
cussion. The substitution of valine for alanine at
this sitewas identiﬁed as a single change in enzyme
SHV-38, encoded by a chromosomal gene, most
probably a direct derivative of the natural K. pneu-
Table 8. Catalytic efﬁciency and inhibition proﬁles of selected complex mutant TEM (CMT) b-lactamases, compared with
their extended-spectrum b-lactamase and inhibitor-resistant TEM (IRT) counterparts
Compound
TEM-3
(Glu39Lys ⁄
Glu104Lys ⁄
Gly238Ser)
[101]a
TEM-59
(Glu39Lys ⁄
Ser130Gly)
[101]a
TEM-89
(Glu39Lys ⁄
Glu104Lys ⁄
Ser130Gly ⁄
Gly238Ser)
[101]a
TEM-6
(Glu104Lys ⁄
Arg164His)
[102]b
TEM-33
(Met69Leu)
[102]b
TEM-109
(Met69Leu ⁄
Glu104Lys ⁄
Arg164His)
[102]b
Catalytic efﬁciency, kcat ⁄Km (mM)1s)1)
AMX 6.2 0.2 1.79 4.0 5.0 4.0
LOT 2.1 <0.01 0.06 0.3 0.01 0.1
CTX 2.0 <0.01 <0.01 0.1 ND 0.1
CAZ 0.1 <0.01 <0.01 0.4 ND 0.2
IC50 for inhibition (lM)
CLA 0.01 100 90 0.01 1.9 0.13
TAZ 0.01 7 8 0.06 2.3 0.27
AMX, amoxycillin; LOT, cephalothin; CTX, cefotaxime; CAZ, ceftazidime; CLA, clavulanic acid; TAZ, tazobactam; ND, not
determinable.
aThis study was carried out with natural TEM variants, TEM-3 (Gln39Lys ⁄Glu104Lys ⁄Gly238Ser), TEM-59 ⁄ IRT-17
(Gln39Lys ⁄ Ser130Gly) and TEM-89 ⁄CMT-3 (Gln39Lys ⁄Glu104Lys ⁄ Ser130Gly ⁄Gly238Ser).
bThis study was carried out with natural TEM variants, TEM-6 (Glu104Lys ⁄Arg164His), TEM-33 ⁄ IRT-5 (Met69Leu) and
TEM-109 ⁄CMT-5 (Met69Leu ⁄Glu104Lys ⁄Arg164His).
Gniadkowski ESBL evolution 21
 2008 The Author
Journal Compilation  2008 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14 (Suppl. 1), 11–32
moniae blaSHV-1. Although SHV-38 was not origi-
nally deﬁned as an ESBL, the mutation was
responsible for a marked increase in catalytic
efﬁciency against cefotaxime and ceftazidime. At
the same time, a decrease of activity against
amoxycillin and cephalothin was observed. How-
ever, the most interesting factor is that the enzyme
hydrolysed imipenem at a signiﬁcant rate. The
E. coli recombinant was clearly resistant to ceftaz-
idime and showed an almost ten-fold increase in
the imipenem MIC, as compared with the SHV-1
producer, even though it remained susceptible to
the compound. It has been hypothesised that the
mutationmay be a starting point in the evolution of
SHV-type enzymes that would combine the ESBL
and carbapenemase activities, with potential
‘improvement’ via accumulation of further
mutations [27]. Recently, three other variants
with mutation Ala146Val (SHV-71, GenBank
AM176546; SHV-72, AM176547; SHV-73,
AM176548), and, interestingly, one with mutation
Ala146Thr (SHV-80, GenBank AM176555), were
identiﬁed; however, no data concerning these
enzymes have been published as yet.
ACCUMULATION OF MUTATIONS IN
TEM AND SHV ESBLS
In-vivo evolution of ESBLs is observed only very
rarely. One occasion, however, was documented
by Rasheed et al. [31], who analysed a series of
E. coli isolates collected over a 3-month course of
infection in a patient who had experienced several
bacteraemic episodes. Comparison of the isolates
revealed a complex pattern of linear and radiative
evolution from a single initial strain, clearly
reﬂecting the antimicrobial treatment proﬁle and
sequence. Among a variety of events observed
was the acquisition of a point mutation by the
blaSHV-1 gene, giving rise to blaSHV-8 (the As-
p179Asn substitution in the protein sequence),
encoding an ESBL. In another study, Bradford
et al. [68] identiﬁed two ESBL genes, differing by
one nucleotide, in a single K. pneumoniae isolate.
The blaTEM-10 gene most probably emerged as a
result of duplication of blaTEM-12, followed by an
additional mutation, determining the Glu240Lys
substitution.
The vast majority of TEM- and SHV-type ESBLs
identiﬁed worldwide in clinical isolates possess
more than one or two mutations, as compared
with TEM-1, TEM-2, SHV-1 and SHV-11. Review
of both the non-synonymous (entailing amino-
acid substitutions) and silent mutations in ESBL
genes allows reconstruction of their evolutionary
history, although often only partially. One such
study considered ten TEM ESBL variants identi-
ﬁed in Poland [10], six of which were probably
related to each other and might originate from the
TEM-25 enzyme reported in France [29] (Fig. 2).
TEM-25 is characterised by amino-acid substitu-
tions Leu21Phe, Gly238Ser and Thr265Met, and
the ‘Polish’ variants acquired numerous further
step-by-step mutations, mostly with a clear func-
tional role, e.g., Glu104Lys, Glu240Lys,
Met182Thr or Arg275Leu.
In some circumstances, combinations of muta-
tions may have an effect when the individual
mutations do not, as was the case of Met182Thr
for example (discussed above) [50]. Two muta-
tions with strictly deﬁned functions may coun-
teract each other, rather than having an additive
effect. Several examples have already been pre-
sented from among the complex mutant b-lacta-
mases possessing both ESBL- and IR-type
substitutions [101,105]. Interestingly, the combi-
nation of the Arg164Ser and Gly238Ser major
ESBL-type mutations also appears to be detri-
mental for enzymic activity against various sub-
strates, especially cefotaxime and cephalothin
[110]. Nevertheless, it has been observed once in
nature, in TEM-8, a strong ESBL that, however,
also has the Glu104Lys mutation [111].
The accumulation of mutations by blaTEM-1
under the selective pressure of cefotaxime, and
Fig. 2. Possible pathways of evolution of TEM-type
extended-spectrum b-lactamases in Poland. Reproduced
with permission from Baraniak et al., Antimicrob Agents
Chemother 2005; 49: 1872–1880.  American Society for
Microbiology.
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their reciprocal effects on each other, were exam-
ined in the directed evolution study by Stemmer
[112]. This study, performed with the in-vitro
DNA shufﬂing approach, revealed that a TEM
mutant bearing three amino acid substitutions,
Glu104Lys, Met182Thr and Gly238Ser, conferred
a 500-fold greater resistance to cefotaxime than
TEM-1. The additional presence of Ala42Gly,
Gly92Ser and Arg241His substitutions, and a
promoter up mutation, G4205A, raised the cefo-
taxime resistance level 32 000-fold. Two subse-
quent studies, using the DNA analogue technique
[113] or in-vivo DNA shufﬂing in a hypermutator
E. coli strain [11], demonstrated again the selec-
tion of the triple Glu104Lys ⁄Met182Thr ⁄Gly238-
Ser mutant, which had, in the meantime, been
identiﬁed as the natural variant TEM-52 [92].
It has been hypothesised that the TEM-52-speciﬁc
set of mutations might be a result of a preferred
evolutionary pathway of accumulation of ESBL-
type mutations, and that the ‘supereffective’
Stemmer’s mutant with six changes might repre-
sent a ‘new-generation’ ESBL soon to appear
under natural conditions [11]. However, Hall
described the likelihood of the future selection
of this set of six amino-acid substitutions as being
rather low. In his site-directed mutagenesis study,
Hall demonstrated a negative effect of mutations
Gly92Ser and Arg241His on the quadruple mu-
tant Ala42Gly ⁄Glu104Lys ⁄Met182Thr ⁄Gly238Ser,
which was already 85 333 times more effective
than TEM-1. This quadruple mutant ESBL might
arise from the acquisition of an Ala42Gly muta-
tion by the natural TEM-52 enzyme [114]. Another
mutation at position 42 (Ala42Val) has already
been observed in nature, although in another
sequence context (TEM-42) [93].
Recently, Weinreich et al. [115] analysed the
pathways of accumulation of the Ala42Gly,
Glu104Lys, Gly238Ser and Met182Thr substitu-
tions, and the promoter mutation, G4205A, which
raises the expression of TEM b-lactamases c. 2.5-
fold. The striking conclusion was that, among 120
possible trajectories of mutation accumulation,
only 18 were accessible for natural selection with
cefotaxime, and the most favourable sequence
was Gly238Ser ﬁ Glu104Lys ﬁ Ala42Gly ﬁ
Met182Thr ﬁ G4205A. Many other possible inter-
mediate combinations of the mutations had either
negative or negligible effects on cefotaxime resis-
tance of E. coli producing the enzymes, and thus
seem unlikely [115].
OTHER CLASS A ESBLS
The evolution of ESBLs by mutation is not limited
to the TEM and SHV families. During the last two
decades, numerous other class A enzymes with
ESBL activity have been identiﬁed, namely the
CTX-M [116], PER [117], VEB [118], GES [119],
BES [7], TLA [120], SFO [121] and BEL [122]
families. The most diversiﬁed are the CTX-M and
GES families, both of which demonstrated inter-
esting examples of activity modiﬁcations due to
amino-acid substitutions. The CTX-M family has
become very prevalent recently in many countries
[8,123,124]. In contrast to TEM and SHV enzymes,
the members of this family have intrinsic ESBL
activity, apparent also in their natural homo-
logues in the genus Kluyvera [125–129], from
which the blaCTX-M genes probably emerged
through several mobilisation events [8]. These
gene pools have undergone evolution, both in
Kluyvera and since their mobilisation. The ﬁrst
phase of this process led to their diversiﬁcation
into ﬁve subfamilies, designated CTX-M-1, CTX-
M-2, CTX-M-8, CTX-M-9 and CTX-M-25, with
inter-subfamily amino-acid identity of £90% [8].
The second phase has been microevolution within
the subfamilies, probably both in Kluyvera and, for
the mobile blaCTX-M genes, elsewhere. This has
produced more than 60 variants so far, with intra-
subfamily amino acid identities of >94% [8]
(http://www.lahey.org/studies/webt.asp). The
very rapid microevolution of CTX-M enzymes
over the last decade is difﬁcult to explain, as is
their enormous ‘epidemiological success’. Recent
crystallographic studies reveal that, in contrast to
TEM- and SHV-type ESBLs, the active site cavity
volume of CTX-M enzymes is not enlarged and
resembles those of TEM-1 and SHV-1 [130,131].
Activity against oxyimino-b-lactam substrates
probably depends on speciﬁc interactions with
side chains of the compounds, particularly via
Ser237 and Asn104 [130–132].
One of the most distinctive features of CTX-M
b-lactamases, recognised since their ﬁrst descrip-
tions, is their substrate preference for cefotaxime
and ceftriaxone and negligible activity against
ceftazidime. The most ‘spectacular’ aspect of the
microevolution of CTX-M enzymes therefore con-
cerns signiﬁcant increases in their ceftazidime-
hydrolysing activity. Mutations at two amino-acid
positions have been found to be mainly respon-
sible for these effects, both in nature and in
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directed evolution studies. Among natural vari-
ants, the replacement of Asp240 by glycine
(Asp240Gly) characterises CTX-M-15, CTX-M-16,
CTX-M-25, CTX-M-27 and CTX-M-32—all with
increased ceftazidimase activity—when com-
pared with CTX-M-3, CTX-M-9, CTX-M-26-like,
CTX-M-14 and CTX-M-1 enzymes, respectively
[133–137]. On the other hand, substitution of
Pro167 was observed in CTX-M-19 (for serine;
Pro167Ser) and CTX-M-23 (for threonine;
Pro167Thr); these are derivatives of CTX-M-14-
and CTX-M-1-like enzymes, respectively
[138,139]. Both positions are located in the active
site regions, Asp240 in the B3 b-strand and Pro167
in the W-loop. The effect of Asp240Gly was
studied at the crystal structure level (CTX-M-27)
and shown not to affect the oxyanion cavity
conformation but, rather, to enhance mobility of
the B3 b-strand and thus, possibly, the protein
ﬂexibility. The same study showed that mutation
Asp240Gly in CTX-M enzymes causes a structural
defect that has a negative effect on thermal
stability, as in ESBL- or IR-type TEM mutants.
This observation again exempliﬁes the trade-off
between activity and stability [131].
Comparison of CTX-M-15 vs. CTX-M-3 (muta-
tion Asp240Gly), and of CTX-M-19 vs. CTX-M-14
(mutation Pro167Ser), shows signiﬁcant increases
in catalytic efﬁciency against ceftazidime
(Table 9). Both mutations also increased activity
against cephaloridine and decreased that against
penicillins, like ESBL-type mutations in the TEM
and SHV families. On the other hand, Asp240Gly
and Pro167Ser differed greatly from each other
with respect to their effects on cefotaxime- and
cefepime-hydrolysing activities, and on the pat-
tern of reductions in activity against penicillins
[138,140]. The kinetic data generally correlated
well with the results on susceptibility. Signiﬁcant
increases in ceftazidime MICs were observed,
especially for producers of enzymes with the
Pro167 substitutions, which were even more
resistant to ceftazidime than to cefotaxime
(Table 10). Despite the diminished enzyme activ-
ity, producers remained highly resistant to pen-
icillins [136,138,139].
When E. coli producing CTX-M-2 was chal-
lenged with ceftazidime, only Pro167Ser mutants
were obtained, with a high selection frequency
[141]. In a similar study, both Asp240Gly and
Pro167Ser mutants of CTX-M-9 were selected
efﬁciently in each of three rounds of the experi-
ment [142]. The substitution Pro167Ser was also
identiﬁed in a variant of the Klebsiella oxytoca
chromosomal b-lactamase, OXY-2-5 (which has
c. 75% homology to CTX-M types [116,125]),
leading to signiﬁcantly increased activity against
ceftazidime [143]. A variety of other substitutions,
conferring or enhancing ceftazidime-hydrolysing
activity, have been found in CTX-M derivatives
during directed evolution studies, some of them
at positions, or of types, known to be responsible
for ESBL activity in the TEM or SHV families, i.e.,
Arg164His, Asp179Gly and Leu169Gln. It is pos-
sible that such CTX-M mutants will appear
naturally in the future [142].
One of the newest families of class A ESBLs are
GES enzymes, previously also called IBC types
Table 9. Catalytic efﬁciency of hydrolysis for selected CTX-M b-lactamases
Substrate
Catalytic efﬁciency, kcat ⁄Km (mM)1s)1)
CTX-M-3
[140]a,c
CTX-M-15
(Asp240Gly) [140]a,c
CTX-M-14
[138]b
CTX-M-19
(Pro167Ser) [138]b
PEN 110 000 4000 1000 300
AMX 1000 500 100 10
LOR 500 1500 30 250
CTX 3500 3000 370 55
CAZ ND 1 ND 0.1
FEP 1 10 40 ND
PEN, benzylpenicillin; AMX, amoxycillin; LOR, cephaloridine; CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime; ND, not
determinable.
aThis study was carried out with CTX-M variants; CTX-M-15 differs from CTX-M-3 only by the Asp240Gly mutation.
bThis study was carried out with CTX-M variants, CTX-M-19 differs from CTX-M-14 (CTX-M-18) only by the Pro167Ser
mutation.
ckcat ⁄Km values were recalculated to mM)1s)1 for comparison purposes.
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[144]. The ﬁrst producer isolate was identiﬁed in
1998 in France but originated from Guiana [119],
and this was soon followed by reports from
several countries throughout the world [145–148].
So far, nine variants have been reported; all are
acquired enzymes with an unknown natural
ancestor. GES b-lactamases are encoded by gene
cassettes present in integrons, observed in Pseu-
domonas aeruginosa and several enterobacterial
species. Despite relatively low afﬁnity, these
enzymes often confer clear resistance to various
b-lactams in clinical isolates [119].
Among several point mutations that distin-
guish GES variants, substitutions for glycine at
position 170 in the W-loop are especially interest-
ing. Gly170 is replaced by asparagine
(Gly170Asn) in the GES-2 enzyme as compared
with GES-1 [146], and by serine (Gly170Ser) in
GES-4 as compared with GES-3 [149]. Ser170 is
also observed in variants GES-5 and GES-6 [150].
As shown in Table 11, the Gly170 replacements in
GES-2 and GES-4 greatly reduced their activities
against oxyimino-b-lactams, especially that of
GES-2 toward ceftazidime. At the same time,
however, these two enzymes exhibited signiﬁ-
cantly increased, although still low-level, hydro-
lytic activity against imipenem. Contradictory
observations have been made regarding cefoxitin,
for which GES enzymes mostly have relatively
high afﬁnity as compared with other class A
b-lactamases, which some types can slowly hydro-
lyse. Whereas GES-2 showed a decrease in cata-
lytic efﬁciency against cefoxitin when compared
with GES-1, GES-4 was more active than GES-3
[146,149].
The heterologous expression of the two pairs
of GES variants reveals the clear impact of the
Gly170 mutations on b-lactam resistance pheno-
Table 11. Catalytic efﬁciency of hydrolysis for selected GES b-lactamases against selected b-lactam compounds
Substrate
Catalytic efﬁciency, kcat ⁄Km (mM)1s)1)
GES-1 [146]a GES-2 (Gly170Asn) [146]a GES-3 [149]b,c GES-4 (Gly170Ser) [149]b,c
PEN 70 96 450 780
AMP ⁄AMX 65 26 190 310
LOR 26 65 120 230
CTX 15 2.5 110 24
CAZ 188 ND 23 1.7
FOX 33 NH NH 110
IPM 0.07 9 NH 81
PEN, benzylpenicillin; AMP, ampicillin; AMX, amoxycillin; LOR, cephaloridine; CTX, cefotaxime; CAZ, ceftazidime; FOX,
cefoxitin; IPM, imipenem; ND, not determinable; NH, not hydrolysed.
aThis study was carried out with natural b-lactamase variants; GES-2 differs from GES-1 only by the Gly170Asn mutation.
bThis study was carried out with natural b-lactamase variants; GES-4 differs from GES-3 only by the Gly170Ser mutation.
ckcat ⁄Km values were recalculated to mM)1s)1 for comparison purposes.
Table 10. Susceptibility of Escherichia coli recombinant strains producing selected CTX-M b-lactamases
b-Lactam
MIC (mg ⁄L)
CTX-M-14 [136]a CTX-M-27 (Asp240Gly) [136]a CTX-M-14 [138]b CTX-M-19 (Pro167Ser) [138]b
AMX >2048 >2048 >512 >512
LOT 512 1024 >512 >512
CTX 16 16 64 4
CAZ 1 8 2 128
FEP 0.5 1 16 4
AMX, amoxycillin; LOT, cephalothin; CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime.
aThis study was carried out with E. coli DH5a transformants producing CTX-M variants, with CTX-M-27 differing from
CTX-M-14 only by the Asp240Gly mutation.
bThe data concern E. coli JM109 transformants producing sole CTX-M-14 (CTX-M-18) or CTX-M-19, differing from each
other only by the Pro167Ser mutation.
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types (Table 12). E. coli recombinants with GES-
2 and GES-4 showed slightly increased imipe-
nem MICs, and this effect was much augmented
for GES-2 when expressed by a P. aeruginosa
transconjugant or for GES-4 in a clinical K. pneu-
moniae isolate. Greater resistance in these latter
species reﬂected the contribution of lower outer
membrane permeability. An E. coli recombinant
with the GES-2 enzyme showed clearly reduced
MICs of ceftazidime and cefotaxime, compared
to one with GES-1, but this effect was not as
marked for the GES-4 producer, as compared to
that with GES-3 [146,149]. On the other hand,
the recombinant expressing GES-4 was highly
resistant to cefoxitin and also had decreased
susceptibility to b-lactamase inhibitor combina-
tions. It should be emphasised that the original
K. pneumoniae with the GES-4 enzyme was
highly resistant to penicillins, ceftazidime, cefox-
itin and b-lactam inhibitor combinations, with
decreased susceptibility also to cefotaxime
and imipenem. This phenotype, broader than
the classical ESBL-mediated phenotype, is one
of the most advanced b-lactam resistance
phenotypes ever observed in Enterobacteriaceae
[149].
CONCLUSION
This review aims to describe mutation during
the evolution of class A ESBLs and its conse-
quences for antimicrobial susceptibility. The
production of b-lactamases is the most thrilling
and intriguing antimicrobial resistance mecha-
nism in Gram-negative bacteria. The high struc-
tural and functional plasticity of these enzymes
creates a large playground for evolution, which
has already produced an amazing variety of
b-lactamase types, collectively compromising the
vast majority of b-lactam antibiotics available for
use. ESBLs represent a prime example of the
factors responsible, in large part, for the global
crisis in the treatment of infections due to
Gram-negative bacteria. Their evolution and
facile dissemination will continue to plague us
in the future, with risks being exacerbated by
the recently discovered over-representation of
hypermutable E. coli strains among ESBL pro-
ducers [151].
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